Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Multi-National Randomized, Double-Blind, Exploratory Study of Abatacept versus Placebo in Preventing the Development of Rheumatoid Arthritis in Adult Subjects with Undifferentiated Inflammatory Arthritis at High Risk for the Development of Rheumatoid Arthritis Revised protocol 2, dated 02-Feb-06, incorporating Amendments 02 and 03; and Pharmacogenetics Blood Sample Amendment Number 01
To assess the proportion of subjects with UA who develop RA as defined by 1987 ARA criteria one year after the start of blinded study medication.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Efficacy of Aripiprazole in Combination with Lithium or Valproate in the Long Term Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Lithium or Valproate Monotherapy Revised Protocol 4 incorporating Amendments 2 & 4 & 6 & 7 + Pharmacogenetics Blood Sample Amendment 1, version 1.0 dated 13-Jul-05
To evaluate the efficacy of aripiprazole in combination with lithium or valproate, compared with placebo in combination with lithium or valproate, as long-term maintenance therapy for patients with Bi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE). Revised Protocol 05, incorporating Protocol Amendment 05 (V2.0, dated 08-Feb-2008), Administrative Letter 01 (dated 13-Jun-2007), Amendment 07 (V1.0, dated 17-Apr-2008), Amendment 11 (V1.0, dated 11-Dec-2008), Amendment 13 (V1.0, dated 30-Apr-2010), Amendment 14 (V1.0, dated 12-Oc t-2010), Administrative Letter 04 (V1.0, dated 15-Oct-2009), Administrative Letter 05 (V1.0, dated 02-Dec-2009), and Administrative Letter 06 (V1.0, dated 12-May-2010) + Pharmacogenetics Blood Sample Amendment Number 1 - Site Specific (V2.0, Date 19-Jan-07). And Protocol Amendment 02 - Site specific (v1.0, date 09-Mar-2007)
*Double-Blind (DB) Period: The primary objective of this study is to compare the time to achieving confirmed protocol-defined complete renal response of lupus glomerulonephritis (defined in Section 3....
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Study to evaluate safety and efficacy in adult subjects with ITP
The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Revised Protocol Number 01, incorporating Amendment 02 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, version 1.0 dated 29-Apr-06
To estimate the 6-month progression free survival rate in patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) with no prior chemotherapy for HCC, treated with 800 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 1/2 Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
-) To assess the safety and tolerability of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MT...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Effects of abatacept in patients who have recently been diagnosed with rheumatoid arthritis
The primary objective for this study is to compare the clinical efficacy of weekly abatacept in combination with MTX to MTX alone in achieving Remission, defined as SDAI ≤ 3, at Week 24.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma. Revised Protocol 03, incorporating Protocol Amendment 04 (V1.0, Date 26-Aug-2008), Protocol Amendment 05 (V1.0, Date 20-Nov-2008), and Protocol Amendment 06 (V1.0, date 05-Jan-2009). + Protocol Amendment 07, country specific - Germany (V1.0, date 19-Dec-2008). + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (V1.0, Date 26-Nov-2007)
The primary objective of the study is to determine the 6-month PFS rate following treatment with BMS-663513 in each arm.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients with Unresectable Stage III or IV Malignant Melanoma Randomized and Treated with Ipilimumab (MDX-010/BMS-734016) at Two Dose Levels. Revised Protocol 06 dated 11-July-2007 Incorporating Amendment(s) 02, 03, 04, 05, 07 and 08. + Protocol Amendment 1 dated 20-Jul-2005
To correlate pre-treatment characteristics of the patient and/or tumor with clinical tumor response in patients with unresectable Stage III and IV melanoma, in order to identify candidate markers pred...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy Revised Protocol 04, incorporating Amendments 03, 06, 08 and 10 (version 1.0, dated 01-Oct-2010) and Administrative Letters 1 and 2. + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0, dated 08-Apr-09)
To compare the overall survival (OS) in women who have progressive disease after one prior chemotherapy regimen for advanced, recurrent or metastatic endometrial cancer treated with ixabepilone versus...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
11
Suivant